Subsequent cross-validation with differentially expressed mRNAs from three independent osimertinib-resistant NSCLC cohorts (GSE222820, GSE232890, GSE255958) identified IGF2BP3 as the candidate (Figures 4B, C). This evidence concerns the gene IGF2BP3 and non-small cell lung carcinoma.